Cutaneous marginal zone B-cell lymphoma

Authors

  • Paula González Campos Hospital of Clinics José de San Martín, Autonomous City of Buenos Aires, Argentina
  • Juan Pablo Valdivieso Hospital of Clinics José de San Martín, Autonomous City of Buenos Aires, Argentina
  • Ariel Sehtman Hospital of Clinics José de San Martín, Autonomous City of Buenos Aires, Argentina
  • Esteban Covian Hospital of Clinics José de San Martín, Autonomous City of Buenos Aires, Argentina
  • Dante Chinchilla Hospital of Clinics José de San Martín, Autonomous City of Buenos Aires, Argentina
  • Mario Marini University of Buenos Aires, Autonomous City of Buenos Aires, Argentina
  • Miguel Ángel Allevato Hospital of Clinics José de San Martín, Autonomous City of Buenos Aires, Argentina
  • María de los Ángeles Juarez Hospital of Clinics José de San Martín, Autonomous City of Buenos Aires, Argentina

Keywords:

cutaneous lymphoma, cutaneous marginal zone lymphoma, doxycycline

Abstract

Cutaneous marginal zone B-cell lymphoma is a lymphoproliferative disorder with benign outcomes. Generally, it presents on the trunk and lower limbs. While unspecific, dermatoscopic findings can provide guidance within the suspected diagnosis. The disease has favorable prognosis. Therapeutic options include intralesional steroids, radiotherapy and surgery. Two confirmed, cutaneous marginal zone B-cell lymphoma case studies are being presented. Case 1, a 90-year-old female subject with a single, purple erythematous tumoral lesion located on the right arm that showed involution following an incisional biopsy. Case 2, a 28-year-old male subject with 3 purple erythematous growths located on the right side, lumbar and homolateral gluteus regions; he later presented with new lesions of similar characteristics on the back of his lower limbs that were treated successfully following a 21-day course of oral doxycycline.

Author Biographies

Paula González Campos, Hospital of Clinics José de San Martín, Autonomous City of Buenos Aires, Argentina

Concurrent medical

Juan Pablo Valdivieso, Hospital of Clinics José de San Martín, Autonomous City of Buenos Aires, Argentina

Concurrent medical

Ariel Sehtman, Hospital of Clinics José de San Martín, Autonomous City of Buenos Aires, Argentina

Staff Physician

Esteban Covian, Hospital of Clinics José de San Martín, Autonomous City of Buenos Aires, Argentina

Chief Resident Physician

Dante Chinchilla, Hospital of Clinics José de San Martín, Autonomous City of Buenos Aires, Argentina

Medical plant

Mario Marini, University of Buenos Aires, Autonomous City of Buenos Aires, Argentina

Consultant Professor of Dermatology

Miguel Ángel Allevato, Hospital of Clinics José de San Martín, Autonomous City of Buenos Aires, Argentina

Head of the Dermatology Division and Professor of Dermatology at the University of Buenos Aires

María de los Ángeles Juarez, Hospital of Clinics José de San Martín, Autonomous City of Buenos Aires, Argentina

Staff Physician, Department of Pathology

References

I. Nicolay J, Marion W. Cutaneous B-cell lymphomas – pathogenesis, diagnostic workup, and therapy. J Dtsch Dermatol Ges 2016;1207-1224.

II. Lima M. Cutaneous primary B-cell lymphomas: from diagnosis to treatment. An Bras Dermatol 2015;90:687-706.

III. Romagosa V. Linfomas cutáneos de células B. Rev Esp Patol2004;37:173-180.

IV. Williemze R, Jaffe E, Burg G, Cerroni L, et ál. WHO-EORTC classification for cutaneous lymphomas. Blood2005;105:3768-3785.

V. Senff N, Noordijk E, Kim Y, Bagot M, et ál. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 2008;112:1600-1609.

VI. Hamada T, Iwatsuki K. Cutaneous lymphoma in Japan: a nationwide study of 1733 patients. J Dermatol 2014;41:3-10.

VII. Consenso Linfomas cutáneos primarios. Sociedad Argentina de Dermatología (SAD). Coordinadores Abeldaño A, et ál. Disponible en: http://www.sad.org.ar/wp-content/uploads/2016/04/linfoma2009.pdf [consulta: junio 2018].

VIII. Pedraz J, Delgado Y, Aragüésa M, Fragab J, et ál. Linfoma cutáneo de células B de la zona marginal tratado con rituximab. Actas Dermosifiliogr 2005;96:593-597.

IX. Mascolo M, Piccolo V, Argenziano G, Costa C, et ál. Dermoscopy pattern, histopathology and immunophenotype of primary cutaneous B-cell lymphoma presenting as a solitary skin nodule. Dermatology 2016;232:203-207.

X. Piccolo V, Mascolo M, Russo T, Staibano S, et ál. Dermoscopy of primary cutaneous B-cell lymphoma (PCBCL). J Am Acad Dermatol 2016;75:137-139.

XI. Wilcox RA. Cutaneous B-cell lymphomas: 2015 update on diagnosis, risk-estratification, and management. Am J Hematol 2015;90:73-76.

XII. Azcune R, Barbarulo AM, Gavazza S, Fontana MI, et ál. Linfomas cutáneos primarios de células B: nuestra experiencia con 22 casos. Dermatol Argent 2008;14:35-45.

XIII. Kollipara R, Hans A, Hall J, Lisle A. A case report of primary cutaneous marginal zone lymphoma treated with intralesional steroids. [en línea]. Dermatol Online J 2015;21:8. Disponible en: http://escholarship.org/uc/item/9s15929m [consulta: enero 2017].

XIV. Soda R, Constanzo A, Cantonetti M, Orlandi A, et ál. Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody. Acta Derm Venereol 2001;81:207-208.

Published

2018-12-10

Issue

Section

Original Articles